ERAS
HEALTHCAREErasca Inc
AI Insight
What's Moving ERAS Today?
No stock-specific AI insight has been generated for ERAS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.33$24.28
$21.26
Fundamentals
Market Cap$5.6B
P/E Ratio—
EPS$-0.93
Dividend Yield—
Dividend / Share—
ROE-69.9%
Profit Margin—
Debt / Equity—
Trading
Volume9.0M
Avg Volume (10D)—
Shares Outstanding311.0M
ERAS News
52 articles- Erasca (Nasdaq: ERAS) prices $550.0M upsized public stock saleStock Titan·Jul 15, 2026
- Form 424B5 Erasca Inc For: 14 July By Investing.comInvesting.com Canada·Jul 15, 2026
- Erasca Announces Pricing of Upsized Public Offering of Common StockThe Manila Times·Jul 14, 2026
- Erasca Plans to Use $550M Offering Proceeds for Drug DevelopmentStock Titan·Jul 14, 2026
- Erasca Announces Pricing of Upsized Public Offering of Common StockGlobeNewswire Inc.·Jul 14, 2026
- Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.GlobeNewswire·Jul 10, 2026
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc.GlobeNewswire·Jul 9, 2026
- ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities Lawsuit - Contact Levi & KorsinskyBusiness Wire·Jul 9, 2026
- ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud LawsuitMorgan County Citizen·Jul 8, 2026
- ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Rolemykxlg.com·Jul 4, 2026
- Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ ListYahoo Finance·Jul 2, 2026
- Tango Therapeutics Rides a New Precision Oncology Trend in 2026Yahoo Finance·Jul 2, 2026
- Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?Yahoo Finance·Jul 2, 2026
- TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 CatalystsYahoo Finance·Jul 2, 2026
- Form 4 Erasca Inc For: 29 June By Investing.comInvesting.com UK·Jun 30, 2026
- Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSSMorningstar·Jun 26, 2026
- Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid TumorsYahoo Finance·Jun 23, 2026
- Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMorningstar·Jun 23, 2026
- VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid TumorsYahoo Finance·Jun 23, 2026
- Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineStreetInsider·Jun 23, 2026
- Erasca (ERAS) Is Down 5.3% After ERAS-0015 Lawsuits Raise Data, Safety And IP ConcernsSimply Wall Street·Jun 22, 2026
- Law Offices of Frank R. Cruz Encourages Erasca, Inc. (ERAS) Shareholders To Inquire About Securities Fraud Class ActionBusiness Wire·Jun 22, 2026
- Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineBusiness Wire·Jun 17, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor HarmPR Newswire·Jun 16, 2026
- ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law FirmBusiness Wire·Jun 12, 2026
- ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firmlincolnjournal.com·Jun 12, 2026
- Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical TrialsYahoo Finance·Jun 11, 2026
- TNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsYahoo Finance·Jun 9, 2026
- Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and PatentsYahoo Finance·Jun 8, 2026
- Erasca Inc. (ERAS) Inspiring Confidence Through Commercial CollaborationsYahoo Finance·Jun 5, 2026
- Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA SaysYahoo Finance·Jun 4, 2026
- Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20Yahoo Finance·Jun 3, 2026
- Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%Motley Fool·May 30, 2026
- Erasca to Present at the Jefferies Global Healthcare ConferenceYahoo Finance·May 27, 2026
- Erasca Patent Dispute Puts ERAS-0015 And Investment Case Under ScrutinyYahoo Finance·May 26, 2026
- Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next DecadeYahoo Finance·May 20, 2026
- Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% RallyMotley Fool·May 18, 2026
- Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterMotley Fool·May 17, 2026
- Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyMotley Fool·May 17, 2026
- Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million MoreMotley Fool·May 17, 2026
Price Data
Open$19.47
Previous Close$19.50
Day High$21.60
Day Low$19.46
52 Week High$24.28
52 Week Low$1.33
52-Week Range
$1.33$24.28
$21.26
Fundamentals
Market Cap$5.6B
P/E Ratio—
EPS$-0.93
Dividend Yield—
Dividend / Share—
ROE-69.9%
Profit Margin—
Debt / Equity—
Trading
Volume9.0M
Avg Volume (10D)—
Shares Outstanding311.0M
About Erasca Inc
Erasca Inc. is an innovative biopharmaceutical company focused on developing targeted therapies for genetically defined cancers, addressing significant unmet needs in oncology. Leveraging its proprietary drug discovery platform that incorporates advanced genomics and precision medicine, Erasca is dedicated to creating treatments that specifically target the mutations driving cancer progression. The company's robust pipeline comprises several clinical-stage candidates designed to inhibit critical tumor growth pathways, positioning Erasca at the forefront of enhancing treatment standards and improving patient outcomes in cancer care. Strategic collaborations within the oncology research community further solidify Erasca's reputation as a key player in the biopharmaceutical sector.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—